Cefminox sodium penetration into prostatic tissue with and without inflammation.

Area of Science:

• Pharmacology
• Urology
• Infectious Diseases

Background:

• Prostatic hyperplasia is a common condition in aging men.
• Understanding antibiotic penetration into prostate tissue is crucial for effective treatment of associated infections.
• Cefminox sodium (CMNX) is a cephalosporin antibiotic with potential use in treating prostatic infections.

Purpose of the Study:

• To determine the concentrations of cefminox sodium (CMNX) in serum and prostatic tissue.
• To investigate whether inflammation associated with prostatic hyperplasia affects CMNX penetration into the prostate.

Main Methods:

• Serum and prostatic tissue samples were collected from 36 patients undergoing treatment for prostatic hyperplasia.
• Concentrations of CMNX were measured in both serum and tissue samples.
• Ratios of CMNX tissue concentration to serum concentration were calculated and compared between patients with and without prostatic inflammation.

Main Results:

• The mean ratio of CMNX concentration in prostatic tissue over serum concentration was 0.11 +/- 0.07 in patients with inflammation.
• The mean ratio was 0.09 +/- 0.06 in patients without inflammation.
• No significant difference in CMNX tissue-to-serum concentration ratios was observed between the two groups.

Conclusions:

• Cefminox sodium (CMNX) penetrates prostatic tissue in patients with prostatic hyperplasia.
• The presence or absence of inflammation in prostatic hyperplasia does not significantly alter CMNX penetration into the prostate.
• These findings suggest that CMNX distribution into prostatic tissue is not influenced by inflammatory status.